Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist investor for complaining about the company's direction without c
Imagine the difference it would make if everyone in your organisation had firsthand experience of living with one of the conditions you help treat. What insights would you gain?
Activist investor Starboard Value has launched a broadside against Pfizer's leadership under chief executive Albert Bourla, claiming at least $20 billion in value – and possibly as much as
In another twist to the tale of Starboard Value's push for change at Pfizer, the activist investor has claimed former executives Ian Read and Frank D'Amelio were bullied into lending their
